PIK3CA and neoplasm: Of the 157 patients, 107 were tested for PIK3CA in tumor and cfDNA samples; in 14 (13%) patients PIK3CA mutations were detected in FFPE tumor samples and 20 (19%) had PIK3CA mutations in cfDNA from plasma with overall agreement between testing in 97 (91%) cases (kappa = 0.65, SE 0.10, 95% CI 0.46–0.85) with sensitivity 86% (95% CI 0.57–0.98), specificity 91% (95% CI 0.84–0.96), positive predictive value 60% (95% CI 0.36–0.81) and negative predictive value 98% (95% CI 0.92–1.00; Table 1).